Highlights

So, I think the large survival benefit seen with PSMA-Lutetium will carry the day, and the fact that it is a setting for which there are few other options for therapy, so, yes, it has side effects as do all therapies, and those will be considered, but I don’t think the side effects will be a problem in patients receiving the drug, or patients being recommended the drug. There are other practical issues that may interfere, but it won’t be side effects.

I think the target [of PNT2002] is good, perhaps there will be room for more, but to be determined’. It’s always more challenging to come in second because then it’s like the world is changing in front of your eyes. And I don’t know the exact timeline for that trial, but in the US, what they can hope for, the makers of that drug, the best thing for them to happen would be that the approval for PSMA-Lutetium takes forever.